Profhylaxis and treatment of hereditary and acquired angioedema at HUB; use of the C1-esterase inhibitor;Profilaxis y tratamiento del angioedema hereditario y adquirido en el HUB; utilización del inhibidor de la C1-esterasa

Farmacia Hospitalaria

Volumn 27, Issue 6, 2003, Pages 346-352

  Pastó Cardona, Lourdes ^a   Bordas Orpinell, J ^a   Mercadal Orfila, G ^a   Perez De La Vara A ^a   Jodar Massanes R ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Acquired angioedema; Berinert ; Bradykinin; C1 esterase inhibitor; Hereditary angioedema

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BERINERT; BRADYKININ; CAPROAMIN; CHLORAMBUCIL; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ICATIBANT; STANOZOLOL; TRANEXAMIC ACID;

ANGIONEUROTIC EDEMA; ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; ENZYME DEFICIENCY; ENZYME INHIBITION; GYNECOMASTIA; HUMAN; PATHOPHYSIOLOGY; PROPHYLAXIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SUBCUTANEOUS TISSUE; UTILIZATION REVIEW; VIRILIZATION;

ADULT; AGED; ANGIONEUROTIC EDEMA; COMPLEMENT C1 INACTIVATOR PROTEINS; FEMALE; FOLLOW-UP STUDIES; HOSPITALS; HUMANS; MALE; MIDDLE AGED;

EID: 0346500881     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Caballero T, López C. Seminario angioedema por déficit de C1-inhibidor. Alergol Inmunol Clin 2000; 15 (extr n° 12): 148-59.
2. López Trascasa M. La deficiencia de inhibidor C1: diagnóstico diferencial y molecular. Alergol Immunol Clin 2000; 15 (extr Núm 2): 148-59.
3. Agostini A, Cicardi M. Hereditary and aquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine 1992; 71: 206-15.
4. Abbas AK, Lichtman AH, Reber JS. Immunología celular y molecular. Ed. Mc Graw-Hill, 2001.
5. Bork K, Barnstedt SE. Treatment of 139 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161 (5): 714-8.
6. Cicardi M, Agostini A. Hereditary angioedema [editorial]. N Engl J Med 1996; 334: 1666-7.
7. Bork K, Barnstedt S-E, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356 (9225): 213-7.
8. Geha RS, Quinti I, Austen KF, et al. Aquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N Eng J Med 1985; 312: 534-40.
9. Markovic SN, Inwards DJ, Frigas EA, et al. Acquired C1 esterase Inhibitor deficiency. Clinical Review. Ann Intern Med 2000; 132: 144-50.
10. Heymann WR, Camden MD. Acquired angioedema. J Am Acad Dermatol 1997; 36: 611-5.
11. Betrián Blasco P, Ferreras Amez A, Uriel Miñana P, et al. Angioedema hereditario (carta al director). An Esp Pediatr 2002; 56: 472.
12. Alsenz J, Lambris JD, Bork K, et al. Acquired C1 inhibitor deficiency type II: replacement therapy with C1-INH and analysis of patients' C1-INH and anti C1-INH autoantibodies. J Clin Invest 1989; 83: 1794-9.
13. Product Information: Danocrine®, danazol. Sanofi Pharmaceuticals, New York, NY, (PI Revised 12/98) reviewed 4/2000.
14. th Ed. US Pharmacopeial Convention, Inc, Rockville, MD, 1998.
15. Product Information: Winstrol®, stanozolol. Sanofi Pharmaceuticals, New York, NY (PI revised 5/97) reviwed 5/2000.
16. Agostini A, Bergamaschini L, Martignoni G, et al. Treatment of accute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy 1980; 44: 299-301.
17. Ultimas novedades sobre AEH en el mundo. Disponible en URL: http:/www.angioedemahereditario.com/novedades.htm. Actualización 21 de agosto de 2002.
18. Kleiner GI, Giclas P, Stadtmauer G, Cunnimgham-Rundles C. Unmasking of acquired autoinmune C1-inhibitor deficiency by an angiotensin-converting enzyme inhibitor. Ann Allergy Asthma Immunol 2001; 86: 461-4.
19. Folleto informativo Berinert® P; Aventis Behring. Revisado febrero 2000.
20. Waytes TA, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. NEJM 1996; 334 (25): 1630-4.